Search Result

Isoforms Recommended:	mTORC1

Results for "

mTORC1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Aminoacyl-tRNA Synthetase (2) AMPK (4) Antibiotic (1) Antifolate (1) Apoptosis (14) Autophagy (29) Bacterial (3) c-Fms (1) DNA-PK (6) DNA/RNA Synthesis (1) Endogenous Metabolite (2) FKBP (2) Fungal (1) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (2) Isotope-Labeled Compounds (1) Kinesin (1) Mitophagy (1) mTOR (62) Phosphatase (1) PI3K (13) Pim (1) PKC (1) Prolyl Endopeptidase (PREP) (2) Proton Pump (1) RABV (1) Ribosomal S6 Kinase (RSK) (1) ROR (1) Small Interfering RNA (siRNA) (2) ULK (1)
By Research Areas:	Cancer (71) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (6)

By Targets:

Akt (1)

Aminoacyl-tRNA Synthetase (2)

AMPK (4)

Antibiotic (1)

Antifolate (1)

Apoptosis (14)

Autophagy (29)

Bacterial (3)

c-Fms (1)

DNA-PK (6)

DNA/RNA Synthesis (1)

Endogenous Metabolite (2)

FKBP (2)

Fungal (1)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Influenza Virus (2)

Isotope-Labeled Compounds (1)

Kinesin (1)

Mitophagy (1)

mTOR (62)

Phosphatase (1)

PI3K (13)

Pim (1)

PKC (1)

Prolyl Endopeptidase (PREP) (2)

Proton Pump (1)

RABV (1)

Ribosomal S6 Kinase (RSK) (1)

ROR (1)

Small Interfering RNA (siRNA) (2)

ULK (1)

By Research Areas:

Cancer (71)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157167

mTORC1-IN-1	mTOR	Neurological Disease Cancer
mTORC1-IN-1 (T1) is a rapamycin homologue (rapalog) and selective *mTORC1* inhibitor. mTORC1-IN-1 regulates cell growth and metabolism and is implicated in a variety of diseases including cancer. mTORC1-IN-1 targets mTORC1 by binding to the FKBP12-FRB complex (docking score = −11.6 kcal/mol) ^[1].

HY-155475

mTORC1-IN-2	mTOR	Cardiovascular Disease
mTORC1-IN-2 (compound H3) is a NO donor compound that alleviates vasodilation and attenuates myocardial hypoxic injury. *mTORC1*-IN-2 upregulates TSC2-P expression and inhibits mTORC1 expression ^[1].

HY-111065

OXA-01

mTOR Cancer

OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively ^[1].
HY-15281

QL-IX-55

mTOR Cancer

QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC₅₀s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively.
HY-120904

AMPK-IN-1

AMPK Metabolic Disease

AMPK-IN-1 is an activator of AMPK (EC₅₀: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way ^[1] .

OXA-01	mTOR	Cancer
OXA-01 is a potent *mTORC1* and *mTORC2* inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively ^[1].

QL-IX-55	mTOR	Cancer
QL-IX-55 is a selective ATP-competitive inhibitor of *mTORC1/2* with IC₅₀s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively.

AMPK-IN-1	AMPK	Metabolic Disease
AMPK-IN-1 is an activator of AMPK (EC₅₀: 551 nM for isoform *α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1*-independent way ^[1] .

HY-124798

Rheb inhibitor NR1 1 Publications Verification	mTOR	Neurological Disease Inflammation/Immunology Cancer
Rheb inhibitor NR1 is a Rheb inhibitor with an IC₅₀ of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven ^T389pS6K1 and increases the phosphorylation of ^S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity ^[1]. ^{(Rheb-IVK: Rheb-dependent mTORC1 kinase activity)}

HY-134904

RMC-6272 RM-006	mTOR	Cancer
RMC-6272 (RM-006) is a bi-steric *mTORC1*-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors ^[1].

HY-10219

Rapamycin Maximum Cited Publications 728 Publications Verification Sirolimus; AY-22989	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-12652

AZD3147

mTOR Cancer

AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC₅₀ value of 1.5 nM. AZD3147 also has a selective effect on PI3K ^[1].

AZD3147	mTOR	Cancer
AZD3147 is a potent, orally active, selective dual inhibitor of *mTORC1* and *mTORC2* with an IC₅₀ value of 1.5 nM. AZD3147 also has a selective effect on PI3K ^[1].

HY-132168

RMC-5552	mTOR	Cancer
RMC-5552 is a potent and selective *mTORC1* inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and *p4EBP1* with IC₅₀s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC₅₀ of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity ^[1].

HY-14581

Palomid 529

5 Publications Verification

P529
mTOR Apoptosis Cancer

Palomid 529 is a potent inhibitor of mTORC1 and mTORC2 complexes.

Palomid 529 5 Publications Verification P529	mTOR Apoptosis	Cancer
Palomid 529 is a potent inhibitor of *mTORC1* and *mTORC2* complexes.

HY-10219S

Rapamycin-d3 Sirolimus-d₃; AY-22989-d₃	mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-14530

Pelitrexol 1 Publications Verification AG 2037	Antifolate	Cancer
Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), a purine biosynthetic enzyme. Pelitrexol also inhibits *mTORC1* by reducing GTP-bound Rheb level, a *mTORC1* obligate activator. Pelitrexol shows robust tumor growth suppression in mice ^[1].

HY-100026

PQR620

3 Publications Verification

mTOR Cancer

PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2 ^[1].
HY-N2517

Dihydroevocarpine

mTOR Cancer

Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity ^[1].
HY-143510

RMC-4627

mTOR Cancer

RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.

PQR620 3 Publications Verification	mTOR	Cancer
PQR620 is an orally bioavailable and selective brain penetrant inhibitor of *mTORC1/2* ^[1].

Dihydroevocarpine	mTOR	Cancer
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the *mTORC1/2* activity ^[1].

RMC-4627	mTOR	Cancer
RMC-4627 is a selective *mTORC1* inhibitor that activates 4EBP1 and inhibits tumor growth.

HY-125355

SEC	Apoptosis	Cancer
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation ^[1] .

HY-N3628

Coronarin A	mTOR Ribosomal S6 Kinase (RSK)	Metabolic Disease Inflammation/Immunology
Coronarin A is an orally active natural compound that inhibits *mTORC1* and *S6K1* to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research ^[1].

HY-107363

FT-1518

mTOR Cancer

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.

FT-1518	mTOR	Cancer
FT-1518 is a new generation selective, potent and oral bioavailable *mTORC1* and *mTORC2* inhibitor, and exhibits antitumor activity.

HY-119665

Asteltoxin	AMPK mTOR	Cancer
Asteltoxin is an inhibitor for extracellular vesicles (EV), which exhibits inhibitory effects towards mitochondrial ATP synthase and mTORC1 activation ^[1].

HY-153789

PI5P4Kγ-IN-1	Others	Cancer
PI5P4Kγ-IN-1 (compound 2) is a selective PI5P4Kγ inhibitor. PI5P4Kγ-IN-1 can be used to signal mTORC1 in MCF-7 breast cancer cells and further characterize PI5P4Kγ in the cells ^[1].

HY-50710

KU-0063794

10+ Cited Publications

mTOR Cancer

KU-0063794 is a potent and specific mTOR inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC₅₀s of 10 nM.

KU-0063794 10+ Cited Publications	mTOR	Cancer
KU-0063794 is a potent and specific *mTOR* inhibitor, inhibiting both the *mTORC1* and *mTORC2* complexes with IC₅₀s of 10 nM.

HY-W058849

MT 63-78	AMPK mTOR Apoptosis	Cancer
MT 63-78 is a specific and potent direct AMPK activator with an EC₅₀ of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and *mTORC1* pathways. MT 63-78 has antitumor effects ^[1].

HY-15247

Vistusertib 20+ Cited Publications AZD2014	mTOR Autophagy Apoptosis	Cancer
Vistusertib (AZD2014) is an ATP competitive *mTOR* inhibitor with an IC₅₀ of 2.81 nM. AZD2014 inhibits both *mTORC1* and *mTORC2* complexes.

HY-13806

XL388 3 Publications Verification	mTOR Autophagy	Cancer
XL388 is a highly potent and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 9.9 nM. XL388 simultaneously inhibits both *mTORC1* and *mTORC2*.

HY-100222

CZ415

3 Publications Verification

mTOR Cancer

CZ415 is a potent and highly selective mTOR inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

CZ415 3 Publications Verification	mTOR	Cancer
CZ415 is a potent and highly selective *mTOR* inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits *mTORC1* and *mTORC2* protein complex.

HY-15248

GDC-0349 2 Publications Verification	mTOR Autophagy	Cancer
GDC-0349 is a potent and selective ATP-competitive *mTOR* inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both *mTORC1* and *mTORC2* complexes.

HY-16956

Onatasertib 2 Publications Verification CC-223; ATG-008	mTOR Apoptosis	Cancer
Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of *mTOR* kinase, with an IC₅₀ value for mTOR kinase of 16 nM. Onatasertib inhibits both *mTORC1* and *mTORC2*.

HY-P5984

Thioether-cyclized helix B peptide, CHBP	mTOR	Others
Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 ^[1].

HY-162147

Nur77 modulator 3	mTOR Autophagy	Inflammation/Immunology
Nur77 modulator 3 (9e) can bind to Nur77 and inhibit TGF-β1-induced α-SMA and COLA1 expression in a Nur77-dependent manner. Nur77 modulator 3 induces Nur77 expression and enhances autophagic flux by inhibiting the *mTORC1* signaling pathway in vitro and in vivo. Nur77 modulator 3 blocks the progression of hepatic fibrosis ^[1].

HY-114384

NV-5138 2 Publications Verification	mTOR	Neurological Disease
NV-5138, a leucine analog, is the first selective and orally active brain *mTORC1* activator, binding to Sestrin2. NV-5138 is used for antidepressant studies ^[1] .

HY-114384B

NV-5138 hydrochloride 2 Publications Verification	mTOR	Neurological Disease
NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain *mTORC1* activator, binding to Sestrin2. NV-5138 hydrochloride is used for antidepressant studies ^[1] .

HY-10422

AZD-8055 40+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive *mTOR* kinase inhibitor with an IC₅₀ of 0.8 nM. AZD-8055 inhibits both *mTORC1* and *mTORC2* ^[1].

HY-153493

PF-04523655	Small Interfering RNA (siRNA)	Metabolic Disease
PF-04523655 is a siRNA directed against RTP801 gene. RTP801 is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

HY-B1787

Sulindac sulfone
Sulindac sulfone is an *mTORC1* pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research ^[1].

HY-153493A

PF-04523655 sodium	Small Interfering RNA (siRNA)	Metabolic Disease
PF-04523655 sodium is a siRNA directed against RTP801 gene. RTP801 sodium is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

HY-10474

Torkinib 15+ Cited Publications PP 242	mTOR Autophagy Mitophagy Apoptosis	Cancer
Torkinib (PP 242) is a selective and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 8 nM ^[1]. PP242 inhibits both *mTORC1* and *mTORC2* with IC₅₀s of 30 nM and 58 nM, respectively .

HY-13003

Torin 1 60+ Cited Publications	mTOR Autophagy	Cancer
Torin 1 is a potent inhibitor of *mTOR* with an IC₅₀ of 3 nM. Torin 1 inhibits both *mTORC1/2 complexes with IC₅₀* values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective *mTOR* inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses *mTORC1* and *mTORC2* in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-16962

CC-115 1 Publications Verification	DNA-PK mTOR	Cancer
CC-115 is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both *mTORC1* and *mTORC2* signaling.

HY-16962A

CC-115 hydrochloride 1 Publications Verification	DNA-PK mTOR	Cancer
CC-115 hydrochloride is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both *mTORC1* and *mTORC2* signaling.

HY-128339

Autogramin-1

Autophagy Cancer

Autogramin-1 potently inhibits autophagy induced by either starvation (IC₅₀=0.17 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.44 μM) ^[1].
HY-128340

Autogramin-2

Autophagy Cancer

Autogramin-2 potently inhibits autophagy induced by either starvation (IC₅₀=0.27 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.14 μM) ^[1].

Autogramin-1	Autophagy	Cancer
Autogramin-1 potently inhibits autophagy induced by either starvation (IC₅₀=0.17 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.44 μM) ^[1].

Autogramin-2	Autophagy	Cancer
Autogramin-2 potently inhibits autophagy induced by either starvation (IC₅₀=0.27 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.14 μM) ^[1].

HY-134922

NS1-IN-1	Influenza Virus	Infection
NS1-IN-1 (compound 3) is a potent *NS1* inhibitor. NS1 is a major influenza A virus virulence factor that inhibits host gene expression. NS1-IN-1 decreases viral protein levels, contributing to the reduction of virus replication. NS1-IN-1 shows antiviral activity by repressing the activity of mTORC1 in a TSC1-TSC2-dependent manner ^[1].

HY-12513

Samotolisib 4 Publications Verification LY3023414	PI3K DNA-PK mTOR Autophagy	Cancer
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and *mTORC1/2* with IC₅₀s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits *mTORC1*/2 at low nanomolar concentrations ^[1] .

HY-15880

CCT007093 2 Publications Verification	Phosphatase Apoptosis Autophagy	Cancer
CCT007093 is an effective protein phosphatase 1D (PPM1D Wip1) inhibitor. Wip1 inhibition can activate the mTORC1 pathway and enhance hepatocyte proliferation after hepatectomy ^[1] .

HY-15272

WAY-600 5 Publications Verification	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-145931

CC214-2	mTOR Autophagy	Cancer
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of *mTORC1* (pS6) and *mTORC2* (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo ^[1] .

HY-128892

EN6 2 Publications Verification	Autophagy	Neurological Disease
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the *ATP6V1A* subunit of the lysosomal v-ATPase. EN6-mediated modification of *ATP6V1A* uncouples v-ATPase from Rag, leading to inhibition of *mTORC1* signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner ^[1].

HY-10423

OSI-027 10+ Cited Publications ASP7486	mTOR Autophagy	Cancer
OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive *mTOR* kinase activity inhibitor with an IC₅₀ of 4 nM. OSI-027 targets both *mTORC1* and *mTORC2* with IC₅₀s of 22 nM and 65 nM, respectively ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

Rapamycin Maximum Cited Publications 728 Publications Verification Sirolimus; AY-22989	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Endogenous metabolite Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-N2517

Dihydroevocarpine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	mTOR
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the *mTORC1/2* activity ^[1].

HY-N0112

Dihydromyricetin 10+ Cited Publications Ampelopsin; Ampeloptin	Infection Flavanonols Structural Classification Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-N0656A

(+)-Usnic acid 2 Publications Verification	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids lichen Plants Disease Research Fields Cancer	mTOR Bacterial Autophagy
(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of *mTOR, and inhibits mTORC1/2* activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity ^[1]. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .

HY-N3628

Coronarin A	Hedychium coronarium Koen. Natural Products Plants Zingiberaceae	mTOR Ribosomal S6 Kinase (RSK)
Coronarin A is an orally active natural compound that inhibits *mTORC1* and *S6K1* to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research ^[1].

HY-18980

Rottlerin 5 Publications Verification Mallotoxin; NSC 56346; NSC 94525	Structural Classification Chalcones Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields Mallotus philippensis Cancer	PKC Autophagy Apoptosis HIV RABV
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation ^[1] . Rottlerin inhibits *HIV-1* integration and Rabies virus (RABV) infection .

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-10219S1

Rapamycin-13C,d3

Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) ^[1]. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks